References
- USFDA. Vaccines Licensed for Immunization and Distribution in the US with Supporting Documents. 2013. Available from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm (accessed October 28, 2016).
- Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999; 17:1075-81; PMID:10545912; https://doi.org/http://dx.doi.org/10.1038/15058
- O'Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001; 18:69-85; https://doi.org/http://dx.doi.org/10.1016/S1389-0344(01)00101-0
- Romero Méndez IZ, Shi Y, HogenEsch H, Hem SL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007; 25:825-33; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2006.09.039
- Kristensen D, Chen D, Cummings R. Vaccine stabilization: Research, commercialization, and potential impact. Vaccine 2011; 29:7122-4; PMID:21651941; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2011.05.070
- Zapata MI, Feldkamp JR, Peck GE, White JL, Hem SL. Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels. J Pharm Sci 1984; 73:3-8; PMID:6694078; https://doi.org/http://dx.doi.org/10.1002/jps.2600730103
- Organization WH. The effects of freezing on the appearance, potency, and toxicity of adsorbed and unadsorbed DTP vaccines. Weekly Epidemiological Record 1980; 55:385-92
- Diminsky D, Moav N, Gorecki M, Barenholz Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 1999; 18:3-17; PMID:10501230; https://doi.org/http://dx.doi.org/10.1016/S0264-410X(99)00149-8
- Milhomme P. Cold chain study: danger of freezing vaccines. Can Commun Dis Rep 1993; 19:33
- Boros CA, Hanlon M, Gold M, Roberton D. Storage at− 3 C for 24 h alters the immunogenicity of pertussis vaccines. Vaccine 2001; 19:3537-42; PMID:11348721; https://doi.org/http://dx.doi.org/10.1016/S0264-410X(01)00063-9
- Milstien JB, Kartoglu Um, Zaffran M, Galazka AM. Temperature sensitivity of vaccines. World Health Organization 2006. Available from http://apps.who.int/iris/bitstream/10665/69387/1/WHO_IVB_06.10_eng.pdf
- Matthias DM, Robertson J, Garrison MM, Newland S, Nelson C. Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine 2007; 25:3980-6; PMID:17382434; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2007.02.052
- Nelson CM, Wibisono H, Purwanto H, Mansyur I, Moniaga V, Widjaya A. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions. Bulletin World Health Organization 2004; 82:99-105; PMID:15042231
- Theo W, Steven T, Nan M, Chris M, John CC. A vaccine cold chain freezing study in PNG highlights technology needs for hot climate countries. Vaccine 2007; 25:691-7; PMID:16968657; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2006.08.028
- Miller N, Harris M. Are childhood immunization programmes in Australia at risk? Investigation of the cold chain in the Northern Territory. Bulletin World Health Organization 1994; 72:401; PMID:8062398
- Techathawat S, Varinsathien P, Rasdjarmrearnsook A, Tharmaphornpilas P. Exposure to heat and freezing in the vaccine cold chain in Thailand. Vaccine 2007; 25:1328-33; PMID:17157419; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2006.09.092
- Matthias D, Robertson J, Garrison M, Newland S, Nelson C. Freezing temperatures in the vaccine cold chain: A systematic literature review. Vaccine 2007; 25:3980-6; PMID:17382434; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2007.02.052
- Nygaard UC, Samuelsen M, Aase A, Løvik M. The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass. Toxicological Sci 2004; 82:515-24; PMID:15456925; https://doi.org/http://dx.doi.org/10.1093/toxsci/kfh287
- Davaalkham D, Ojima T, Wiersma S, Lkhagvasuren T, Nymadawa P, Uehara R, Watanabe M, Oki I, Nakamura Y. Administration of hepatitis B vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide survey. J Epidemiol Community Health 2007; 61:578-84; PMID:17568048; https://doi.org/http://dx.doi.org/10.1136/jech.2006.051375
- Mansoor O, Pillans P. Vaccine adverse events reported in New Zealand 1990-5. N Z Med J 1997; 110:270-2; PMID:9269289
- Frankel AE, Kuo SR, Dostal D, Watson L, Duesbery NS, Cheng CP, Cheng HJ, Leppla SH. Pathophysiology of anthrax. Front Biosci 2009; 14:4516-24; https://doi.org/http://dx.doi.org/10.2741/3544
- Menon P, Sahai G, Joshi V, Murthy R, Boparai M, Thomas A. Field trial on frozen and thawed tetanus toxoid. Indian J Med Res 1976; 64:25-32; PMID:1270098
- Patrick L, Simona Z, Carole T-B, Harouna DM, Placide G, Oumar YB, Michel Z. Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad. Bull WHO 2014; 92:86-92; PMID:24623901
- Zipursky S, Djingarey MH, Lodjo J-C, Olodo L, Tiendrebeogo S, Ronveaux O. Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin. Vaccine 2014; 32:1431-5; PMID:24559895; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2014.01.038
- Lydon P, Zipursky S, Tevi-Benissan C, Djingarey MH, Gbedonou P, Youssouf BO, Zaffran M. Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad. Bull World Health Organ 2014; 92:86-92; PMID:24623901; https://doi.org/http://dx.doi.org/10.2471/BLT.13.123471
- WHO. Controlled temperature chain. World Health Organization. Available from http://www.who.int/immunization/programmes_systems/supply_chain/resources/Controlled-Temperature-Chain-FAQ.pdf (accessed December 21, 2016).
- WHO. Revolutionary meningitis vaccine breaks another barrier; first to gain approval to travel outside cold chain. World Health Organization 2012. Available from http://www.who.int/immunization/newsroom/menafrivac_20121114/en/ (accessed August 22, 2016).
- Engstrom JD, Lai ES, Ludher BS, Chen B, Milner TE, Williams RO, 3rd, Kitto GB, Johnston KP. Formation of stable submicron protein particles by thin film freezing. Pharm Res 2008; 25:1334-46; PMID:18286357; https://doi.org/http://dx.doi.org/10.1007/s11095-008-9540-4
- Zhang M, Li H, Lang B, O'Donnell K, Zhang H, Wang Z, Dong Y, Wu C, Williams RO, 3rd. Formulation and delivery of improved amorphous fenofibrate solid dispersions prepared by thin film freezing. Eur J Pharm Biopharm 2012; 82:534-44; PMID:22974985; https://doi.org/http://dx.doi.org/10.1016/j.ejpb.2012.06.016
- Li X, Thakkar SG, Ruwona TB, Williams RO, Cui Z. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution. J Control Release 2015; 204:38-50; PMID:25735896; https://doi.org/http://dx.doi.org/10.1016/j.jconrel.2015.02.035
- Watanabe T, Kitabatake N, Doi E. Method for the Accurate Measurement of Freezing-induced Denaturation of Ovalbumin with 5, 5′-Dithiobis-(2-nitrobenzoic acid). Biosci Biotechnol Biochem 1994; 58:359-62; https://doi.org/http://dx.doi.org/10.1271/bbb.58.359
- Photchanachai S, Mehta A, Kitabatake N. Heating of an ovalbumin solution at neutral pH and high temperature. Biosci Biotechnol Biochem 2002; 66:1635-40; PMID:12353621; https://doi.org/http://dx.doi.org/10.1271/bbb.66.1635
- Weijers M, Barneveld PA, Cohen Stuart MA, Visschers RW. Heat-induced denaturation and aggregation of ovalbumin at neutral pH described by irreversible first-order kinetics. Protein Sci 2003; 12:2693-703; PMID:14627731; https://doi.org/http://dx.doi.org/10.1110/ps.03242803
- Koch C, Jensen SS, Oster A, Houen G. A comparison of the immunogenicity of the native and denatured forms of a protein. APMIS 1996; 104:115-25; PMID:8619913; https://doi.org/http://dx.doi.org/10.1111/j.1699-0463.1996.tb00696.x
- Braun LJ, Tyagi A, Perkins S, Carpenter J, Sylvester D, Guy M, Kristensen D, Chen D. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine 2009; 27:72-9; PMID:18973782; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2008.10.027
- Jezek J, Chen D, Watson L, Crawford J, Perkins S, Tyagi A, Jones Braun L. A heat-stable hepatitis B vaccine formulation. Hum Vaccin 2009; 5:529-35; PMID:19556877; https://doi.org/http://dx.doi.org/10.4161/hv.5.8.8600
- Xue H, Yang B, Kristensen DD, Chen D. A freeze-stable formulation for DTwP and DTaP vaccines. Hum Vaccin Immunother 2014; 10:3607-10; PMID:25668668; https://doi.org/http://dx.doi.org/10.4161/21645515.2014.980195
- Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 1992; 10:S99-S101; PMID:1335671; https://doi.org/http://dx.doi.org/10.1016/0264-410X(92)90557-Z
- Wiedermann G, Ambrosch F, André F, Delem A, D'hondt E, Safary A. Thermostability of an inactivated hepatitis A vaccine stored at 37 C for one week. J Medical Virol 1994; 44:442-; PMID:7897377; https://doi.org/http://dx.doi.org/10.1002/jmv.1890440423
- Wiedermann G, Ambrosch F. Immunogenicity of an inactivated hepatitis A vaccine after exposure at 37 C for 1 week. Vaccine 1994; 12:401-2; PMID:8023546; https://doi.org/http://dx.doi.org/10.1016/0264-410X(94)90113-9
- Lee S-M, Petermann R, Porte Q, Berezuk G, Crowe B, Shirtz J. Long-term thermal stability of group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine. Hum Vaccin 2007; 3:27-32; PMID:17264684; https://doi.org/http://dx.doi.org/10.4161/hv.3.1.3749
- Hansen B, Sokolovska A, HogenEsch H, Hem SL. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 2007; 25:6618-24; PMID:17681647; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2007.06.049
- Hansen B, Soung G, Song L, Egan PM, Capen R, HogenEsch H, Mancinelli R, Hem SL. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 2009; 27:888-92; PMID:19071182; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2008.11.078
- Vessely C, Estey T, Randolph TW, Henderson I, Cooper J, Nayar R, Braun LJ, Carpenter JF. Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J Pharmaceutical Sci 2009; 98:2970-93; PMID:18680175; https://doi.org/http://dx.doi.org/10.1002/jps.21498
- Geeraedts F, Saluja V, ter Veer W, Amorij J-P, Frijlink HW, Wilschut J, Hinrichs WL, Huckriede A. Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures. AAPS J 2010; 12:215-22; PMID:20195930; https://doi.org/http://dx.doi.org/10.1208/s12248-010-9179-z
- Amorij J, Meulenaar J, Hinrichs W, Stegmann T, Huckriede A, Coenen F, Frijlink H. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 2007; 25:6447-57; PMID:17673338; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2007.06.054
- Murugappan S, Patil HP, Kanojia G, ter Veer W, Meijerhof T, Frijlink HW, Huckriede A, Hinrichs WL. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants. Eur J Pharm Biopharm 2013; 85:716-25; PMID:23933147; https://doi.org/http://dx.doi.org/10.1016/j.ejpb.2013.07.018
- Hassett KJ, Cousins MC, Rabia LA, Chadwick CM, O'Hara JM, Nandi P, Brey RN, Mantis NJ, Carpenter JF, Randolph TW. Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization. Eur J Pharm Biopharm 2013; 85:279-86; PMID:23583494; https://doi.org/http://dx.doi.org/10.1016/j.ejpb.2013.03.029
- Hassett KJ, Meinerz NM, Semmelmann F, Cousins MC, Garcea RL, Randolph TW. Development of a highly thermostable, adjuvanted human papillomavirus vaccine. Eur J Pharm Biopharm 2015; 94:220-8; PMID:25998700; https://doi.org/http://dx.doi.org/10.1016/j.ejpb.2015.05.009
- Saboo S, Tumban E, Peabody J, Wafula D, Peabody DS, Chackerian B, Muttil P. Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus. Mol Pharm 2016; 13:1646-55; PMID:27019231; https://doi.org/http://dx.doi.org/10.1021/acs.molpharmaceut.6b00072
- Mensink MA, Nethercott MJ, Hinrichs WL, van der Voort Maarschalk K, Frijlink HW, Munson EJ, Pikal MJ. Influence of Miscibility of Protein-sugar lyophilizates on their storage stability. AAPS J 2016; 18(5):1225-32: 1-8; PMID:26377333
- Kunda NK, Wafula D, Tram M, Wu TH, Muttil P. A stable live bacterial vaccine. Eur J Pharm Biopharm 2016; 103:109–117; PMID:27020530
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000; 203:1-60; PMID:10967427; https://doi.org/http://dx.doi.org/10.1016/S0378-5173(00)00423-3
- Pisal S, Wawde G, Salvankar S, Lade S, Kadam S. Vacuum foam drying for preservation of LaSota virus: effect of additives. AAPS PharmSciTech 2006; 7:60; PMID:17025241; https://doi.org/http://dx.doi.org/10.1208/pt070360
- Chen D, Kapre S, Goel A, Suresh K, Beri S, Hickling J, Jensen J, Lal M, Preaud JM, Laforce M, et al. Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method. Vaccine 2010; 28:5093-9; PMID:20478345; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2010.04.112
- Maa YF, Zhao L, Payne LG, Chen D. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J Pharm Sci 2003; 92:319-32; PMID:12532382; https://doi.org/http://dx.doi.org/10.1002/jps.10294
- Yu Z, Johnston KP, Williams RO, 3rd. Spray freezing into liquid versus spray-freeze drying: influence of atomization on protein aggregation and biological activity. Eur J Pharm Sci 2006; 27:9-18; PMID:16188431; https://doi.org/http://dx.doi.org/10.1016/j.ejps.2005.08.010
- Clausi A, Cummiskey J, Merkley S, Carpenter JF, Braun LJ, Randolph TW. Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J Pharm Sci 2008; 97:5252-62; PMID:18398901; https://doi.org/http://dx.doi.org/10.1002/jps.21390
- Clausi AL, Morin A, Carpenter JF, Randolph TW. Influence of protein conformation and adjuvant aggregation on the effectiveness of aluminum hydroxide adjuvant in a model alkaline phosphatase vaccine. J Pharm Sci 2009; 98:114-21; PMID:18506831; https://doi.org/http://dx.doi.org/10.1002/jps.21433
- Watts AB, Wang YB, Johnston KP, Williams RO, 3rd. Respirable low-density microparticles formed in situ from aerosolized brittle matrices. Pharm Res 2013; 30:813-25; PMID:23229856; https://doi.org/http://dx.doi.org/10.1007/s11095-012-0922-2
- Sloat BR, Sandoval MA, Hau AM, He Y, Cui Z. Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J Control Release 2010; 141:93-100; PMID:19729045; https://doi.org/http://dx.doi.org/10.1016/j.jconrel.2009.08.023